Anthropic acquired stealth biotech startup Coefficient Bio in a $400M stock deal, adding ~10 drug-discovery AI specialists to its life sciences team.
Anthropic acquired Coefficient Bio, an AI-powered drug discovery startup founded just eight months ago by Samuel Stanton and Nathan C. Frey — both former Genentech Prescient Design researchers. The deal was structured as a $400M stock transaction. The ~10-person team will join Anthropic's health and life sciences division. This follows Anthropic's October 2024 launch of Claude for Life Sciences, signaling a deliberate vertical push into biotech.
This acquisition signals that Anthropic is investing in domain-specific model capabilities for biology, not just general-purpose Claude APIs. Developers building on Claude for life sciences use cases — protein modeling, clinical trial analysis, drug interaction prediction — should expect new specialized endpoints and fine-tuned models to emerge from this team. Nothing ships today, but the technical roadmap just became clearer.
If you're building bioinformatics tooling, test Claude's current scientific reasoning limits by running a complex drug-gene interaction query through the Claude API this week — benchmark it against GPT-4o on specificity and hallucination rate so you have a baseline before Anthropic's new capabilities drop.
Open console.anthropic.com and create a new API key if you don't have one
Tags
Sources
Related
Signals by role
Also today
Tools mentioned